SYSTEMATIC REVIEW AND META-ANALYSIS OF BRIAKINUMAB, A FULLY HUMAN INTERLEUKIN 12/23 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

被引：0
|
作者：
Vsn, M.
Mothe, R. K.
Hyderboini, R. K.
Likhar, N.
Ganji, K.
Singuru, S.
Dang, A.
机构：
[1] MarksMan Healthcare Solut LLP, Hlth Econ & Outcomes Res HEOR, Navi Mumbai, India
[2] RWE, Navi Mumbai, India
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.494
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS5
引用
收藏
页码：A123 / A123
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial
    Kimball, A. B.
    Gordon, K. B.
    Valdes, J. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S54 - S54
  • [22] Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis
    Aljefri, Yara E.
    Ghaddaf, Abdullah A.
    Alkhunani, Tala A.
    Alkhamisi, Taif A.
    Alahmadi, Rana A.
    Alamri, Awadh M.
    Alraddadi, Ali A.
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [23] Interleukin-12/23 vs Interleukin-23 Inhibitors in Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis
    Pasam, Ravi Teja
    Gautam, Misha
    Venugopalan, Sruthi
    Mohan, Babu
    Navaneethan, Udaykumar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S834 - S835
  • [24] A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
    Gordon, Kenneth B.
    Langley, Richard G.
    Gottlieb, Alice B.
    Papp, Kim A.
    Krueger, Gerald G.
    Strober, Bruce E.
    Williams, David A.
    Gu, Yihua
    Valdes, Joaquin M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (02) : 304 - 314
  • [25] Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis
    Tian, Fangyuan
    Chen, Zhaoyan
    Xu, Ting
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (06) : 2342 - 2350
  • [26] Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
    Sawyer, Laura M.
    Malottki, Kinga
    Sabry-Grant, Celia
    Yasmeen, Najeeda
    Wright, Emily
    Sohrt, Anne
    Borg, Emma
    Warren, Richard B.
    PLOS ONE, 2019, 14 (08):
  • [27] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    Fox, T.
    Huang, J.
    Papavassilis, C.
    Liang, E.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758
  • [28] Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment
    Jacobs, A.
    Rosumeck, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2015, 40 (07) : 810 - 811
  • [29] Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis
    Zhu, Teng
    Ma, Lin
    CONTRAST MEDIA & MOLECULAR IMAGING, 2022, 2022
  • [30] Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
    Armstrong, April
    Fahrbach, Kyle
    Leonardi, Craig
    Augustin, Matthias
    Neupane, Binod
    Kazmierska, Paulina
    Betts, Marissa
    Freitag, Andreas
    Kiri, Sandeep
    Taieb, Vanessa
    Slim, Mahmoud
    Gomez, Natalie Nunez
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2022, 12 (08) : 1777 - 1792
12345